Robust Wald-Type Tests under Random Censoring with Applications to
  Clinical Trial Analyses by Ghosh, Abhik et al.
Robust Wald-Type Tests under Random Censoring
with Applications to Clinical Trial Analyses
Abhik Ghosh1, Ayanendranath Basu1∗ and Leandro Pardo2
1 Indian Statistical Institute, Kolkata, India
2 Complutense University, Madrid, Spain
∗Corresponding author. Email: ayanbasu@isical.ac.in
Abstract
Randomly censored survival data are frequently encountered in applied sciences including
biomedical or reliability applications and clinical trial analyses. Testing the significance of
statistical hypotheses is crucial in such analyses to get conclusive inference but the existing
likelihood based tests, under a fully parametric model, are extremely non-robust against outliers
in the data. Although, there exists a few robust parameter estimators (e.g., M-estimators and
minimum density power divergence estimators) given randomly censored data, there is hardly
any robust testing procedure available in the literature in this context. One of the major
difficulties in this context is the construction of a suitable consistent estimator of the asymptotic
variance of M-estimators; the latter is a function of the unknown censoring distribution. In this
paper, we take the first step in this direction by proposing a consistent estimator of asymptotic
variance of the M-estimators based on randomly censored data without any assumption on
the form of the censoring scheme. We then describe and study a class of robust Wald-type
tests for parametric statistical hypothesis, both simple as well as composite, under such set-
up, along with their general asymptotic and robustness properties. Robust tests for comparing
two independent randomly censored samples and robust tests against one sided alternatives are
also discussed. Their advantages and usefulness are demonstrated for the tests based on the
minimum density power divergence estimators with specific attention to clinical trial analyses.
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1 Introduction
Randomly censored survival data are frequently encountered in different applied sciences including
biomedical and reliability applications. Some observed life-times are often seen to be right censored
since the subject may still be alive at the end of study period or may have been lost to follow-up
within the study period. In most clinical trials, the censoring mechanism of patients depends on
several unknown quantities and hence is generally assumed to be random and independent of the
main response (e.g., patients lifetime). Mathematically, n subjects have life-time (X) measures
denoted by X1, . . . , Xn, which are independent and identically distributed (i.i.d.) with distribution
GX . However, due to right censoring, we only observe Zi = min (Xi, Ci) and δi = I(Xi ≤ Ci),
for i = 1, . . . , n, where I(A) denotes the indicator function of the event A and C1, . . . , Cn denote
n i.i.d. realizations of the censoring variable C having distribution GC . We assume that C is
independent of X and wish to do inference about the distribution of X based on the observed data
{Zi, δi}i=1,...,n.
Several non-parametric and semi-parametric inference procedures are available in the literature
to handle such data based on the Kaplan-Meier product-limit (KMPL) estimator of GX [18], given
by
ĜX(x) = 1−
n∏
i=1
[
1− δ[i,n]
n− i+ 1
]I(Z(i,n)≤x)
, (1)
where Z(i,n) denote the i-th order statistic in {Z1, · · · , Zn} and δ[i,n] is the value of the corresponding
δ (i-th concomitant). Under the presence of random censoring, this popular estimator is the
non-parametric maximum likelihood estimator (MLE) of the distribution function GX and enjoys
many optimality properties. However, such non-parametric (or related semi-parametric) inference
about X is generally much less efficient compared to the procedures implemented under some fully
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parametric distributional assumptions. See Chapter 8 of [15] for advantages of such fully parametric
modeling; these include greater efficiency, easily interpretable parameter estimates and possibility
of predictions from fitted models. In medical sciences, such parametric assumptions can often be
made from prior knowledge about the field or from similar experiments done in past (with same
disease/drugs). From an empirical exploration of the data, we can also get an idea about the
underlying parametric model; for example, a linear plot of the empirical estimate of cumulative
hazard, [− log(1− ĜX(x))], over lifetime x in a log-log scale indicates the suitability of the Weibull
family to be a possible candidate for modeling the underlying data (see Figure 1 for some clinical
trial examples).
Classical fully parametric inference procedures are mainly based on the maximum likelihood
approach; see [5–7, 19, 22] among many others. However, as in several other types of data, the
maximum likelihood methods for censored data are also highly non-robust with respect to outliers.
Since outliers are not uncommon in real-life applications, suitable robust procedures having good
model efficiency are always very useful. However, the robustness issue under survival data has been
ignored in the literature for a long time and even now has only got some scattered attention. A
family of general M-estimators under randomly censored data has been introduced by [28]. A par-
ticular M-estimator based on the density power divergence (DPD) of [2] under a fully parametric
set-up has been investigated by [1], exhibiting robust performances with high efficiency. These pro-
cedures have recently been extended to a general regression-type set-up with stochastic covariates
and randomly censored response [9]. Robust estimators under semi-parametric accelerated failure
time (AFT) models have been developed by [23, 29, 30]. However, the current literature seems to
offer very little in terms of robust testing of statistical hypotheses under randomly censored data,
although the issue is of high practical importance in real-life problems. To further motivate the
sheer need of a robust testing approach, in particular for medical statistics, let us consider a few
clinical trial data examples.
Motivating Examples:
We focus on four clinical trials each having two groups denoted by Arm A and Arm B, respectively,
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(a) Veteran Lung Cancer Trial (b) Small-Cell Lung Cancer Trial
(c) Breast and Ovarian Cancer Trial (d) Gastric Carcinoma Trial
Figure 1: Empirical Cumulative hazards (in log-log scale) for different two-arm clinical trial data
(red dashed: Arm A, blue dash-dotted: Arm B, solid black: Combined data)
related to lung cancer, Breast and Ovarian Cancer (BOC) and Gastric Carcinoma; the two arms
denote two groups of patients receiving two different treatments (one of which may be the control).
The details of these trials are provided in Section 6; but the empirical estimates of cumulative
hazards based on the the right-censored lifetime data from these four trials are plotted in the log-log
scale in Figure 1 for both the arms separately as well as for the combined data. Note that, except at
the extreme ends, either due to unrealistic early failures or outlying observations, the major part of
these plots can be fitted well by a straight line which led us to the Weibull model having cumulative
hazard Λ(x) = abxb with a, b > 0 being the scale and the shape parameters, respectively. So, we
can analyze these clinical trials more efficiently by fitting a Weibull model to the data; the inference
will be based on the estimated values of the parameter θ = (a, b)T for each arm separately followed
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Table 1: Parameter estimates for the Weibull model fitted to the four clinical trial datasets
Clinical Trial Dataset Arm Estimate of (a, b)
MLE MDPDE at α = 0.5 MDPDE at α = 1
Veteran Lung Cancer Arm A (123, 0.99) (125, 0.96) (122, 0.97)
Arm B (118, 0.76) (95, 0.92) (85, 0.99)
Overall (121, 0.85) (111, 0.93) (103, 0.97)
Small-Cell Lung Cancer Arm A (987, 1.53) (918, 1.51) (731, 1.83)
Arm B (665, 1.36) (480, 1.81) (428, 2.10)
Overall (830, 1.38) (724, 1.47) (584, 1.78)
Breast & Ovarian Cancer Arm A (4621, 1.79) (4807, 1.62) (4881, 1.54)
Arm B (1769, 1.28) (1766, 1.34) (1735, 1.48)
Overall (3075, 1.26) (3030, 1.24) (2798, 1.32)
Gastric Carcinoma Arm A (760, 1.15) (660, 1.48) (600, 1.75)
Arm B (628, 0.79) (376, 1.11) (359, 1.18)
Overall (700, 0.92) (593, 1.07) (543, 1.19)
by suitable comparisons. Table 1 presents the MLE of these parameters for all four trials along
with the two robust estimators from the family of MDPDEs of [1] under the Weibull model (See
Section 2.2 for definitions). These robust estimators, depending on the value of tuning parameter
α, are slightly less efficient under pure data but extremely robust against data contamination.
Note that, for all the trials, the MLE and the robust estimators differ from each other to a certain
extent, sometimes substantially. For the inference to be conclusive, the practitioner would want
to know whether these differences between the estimators are indeed statistically significant due
to presence of outlying observations or just due to sampling fluctuations. This depends on many
factors like sample size, variance of the estimators, etc., and has to be rigorously confirmed through
tests of hypothesis. There could be several important hypotheses to be tested in such situations.
Is there a small proportion of outliers which, while of interest on their own, influence the final
decision by their presence? Do the model parameters for the two arms differ significantly only due
to the presence of outliers (or are forced to look similar by the outliers masking a true difference)?
Can a real improvement of treatment over control be hidden by a small set outliers? When we
are suspicious about the presence of few extreme observations in data, which is quite common in
practice, the inference obtained by using the MLE based tests to answer these questions can be
often misleading. For example, in the Veteran Lung Cancer trial, the MLE of the shape parameter
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(b) differs significantly between arms and the associated Wald test rejects the hypothesis of their
equality in two arms (bA = bB) at standard significance levels. However, their robust estimates
are substantially closer, raising the suspicion that the earlier observed difference might be due to
a small proportion of discordant observations. But, to prove this intuitive conclusion rigorously,
we definitely need an appropriate testing procedures to robustly compare the two arms. Similar
erroneous inference can also be observed for testing the hypothesis that the shape parameter (b)
for arm B data of the BOC trial is 1.45 using the likelihood based methods; such a test rejects
this hypothesis based on the full data but accepts it after removing the outliers from the data.
Instead of the two-step outlier identification methods, a robust test of hypothesis procedure based
on appropriate robust estimators (like MDPDE) will always be extremely effective and efficient in
such cases; only having robust estimators itself will not suffice for a complete practical conclusion.
The MDPDEs of b for arm B data of the BOC trial, as reported in Table 1, are very close to the
null value 1.45, but we need to check if they are significantly close, and that can only be done
through a proper statistical test. 
Therefore, nonavailability of robust test procedures under random censoring predominantly
limits the use of robust estimators too and leads to the false conclusion in presence of outliers
while using the only available likelihood based tests. The primary obstacle in constructing robust
tests has been the unknown censoring distribution which is always involved in the asymptotic
distribution of the robust estimators. Hence, consistently estimating the asymptotic variance of
the robust estimators based on randomly censored data has been the main challenge. In this
paper, we address this important problem by developing a class of robust Wald-type tests under
randomly censored data. For this purpose we develop a consistent estimator of the asymptotic
variance of the M-estimators with an unknown censoring scheme. As a particular case, we study
the advantages of the MDPDE based Wald-type tests under the fully parametric set-up; high
efficiency of the MDPDE translates to high power for the corresponding tests. We describe the
procedure for testing parametric hypothesis under both one and two sample problems. Besides
demonstrating their robustness properties, we illustrate the usefulness of the proposed Wald-type
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tests in robust inference and comparison of clinical trial groups. All real datasets introduced as
motivating examples are further studied in details using our proposal along with two additional
interesting datasets.
2 Robust Estimators under Random Censoring
2.1 General M-estimators
Although a few early approaches were previously available [14, 16, 21, 24, 25], a formal M-estimation
theory for randomly censored data was first developed by [27, 28] with asymptotic results under
simpler verifiable conditions. Under the notation of Section 1, consider the problem of estimating
a parameter θ = θ(GX) from a parameter space Θ ⊆ Rp (p ≥ 1). In the fully parametric set-up,
we model GX by a parametric family of distributions, say F = {Fθ : θ ∈ Θ ⊆ Rp}, with θ being
the parameter of interest. Let θ0 denote the true value of the parameter.
Definition 2.1 Given a function ψ(x;θ) : R×Θ 7→ Rp, the corresponding M-estimator of θ under
random censoring is defined as a solution to the estimating equation
∫
ψ(x;θ)dĜX(x) = 0, where
ĜX(·) is the KMPL estimator of GX given by (1), and the ψ-function satisfies
∫
ψ(x;θ0)dGX(x) = 0. (2)
Under Assumption (2), M-estimators are Fisher consistent and the associated estimating equation
is unbiased. In practice, while solving it numerically, we may face the problem of multiple roots
and some additional techniques are required in such cases.
Whenever ψ(x;θ) is continuous and bounded in θ, there exists a strongly consistent (for θ0)
sequence of M-estimators and any sequence of M-estimators converges to θ0 with probability one
[28, Theorem 3] under the assumptions listed in Appendix A. Further, if we define the random
variables Z = min(X,C) and δ = I(X ≤ C) and the sub-distribution functions GZ,0(z) = P (Z ≤
z, δ = 0) and GZ,1(z) = P (Z ≤ z, δ = 1), then the distribution of Z is GZ = GZ,0 +GZ,1. For any
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real valued function φ(x), let us denote UZ,δ(φ) = φ(Z)γ0(Z)δ+γ1(Z;φ)(1−δ)−γ2(Z;φ)−
∫
φdGX ,
where
γ0(x) = exp
{∫
I(z < x)dGZ,0(z)
1−GZ(z)
}
, γ1(x;φ) =
∫
I(z > x)φ(z)γ0(z)
1−GZ(x) dGZ,1(z),
and γ2(x;φ) =
∫
φ(z)γ0(z)γ(min{x, z})dGZ,1(z), with γ(x) =
∫
I(z < x)dGZ,0(z)
[1−GZ(z)]2
,
and define the p× p matrices Λ(ψ;θ) = ∫ ∂∂θψ(x;θ)dGX(x) and
C(ψ;θ) = E
[
(UZ,δ(ψ1(·;θ)), · · · , UZ,δ(ψp(·;θ)))T (UZ,δ(ψ1(·;θ)), · · · , UZ,δ(ψp(·;θ)))
]
.
Then, assuming that ψ(x;θ) is differentiable in θ in a neighborhood of true θ0, along with As-
sumptions (A1)–(A6) listed in Appendix A, it has been shown that [28, Theorem 5]
√
n
(
θ̂n − θ0
)
is asymptotically normal with mean 0p, the p-vector of zeros, and covariance matrix Σ(ψ;θ0) =
Λ(ψ;θ0)
−1C(ψ;θ0)Λ(ψ;θ0)−1, for any consistent sequence {θ̂n} of corresponding M-estimators.
2.2 The Minimum Density Power Divergence Estimator
A particular fully parametric M-estimator with high efficiency has been proposed by [1] based on
the DPD measure. The DPD measure between two densities g and f , with respect to a common
dominating measure, is defined as
dα(g, f) =

∫ [
f1+α −
(
1 +
1
α
)
fαg +
1
α
g1+α
]
, for α > 0,∫
g log(g/f), for α = 0.
(3)
When we have n i.i.d. observations Y1, . . . , Yn, having true density g, modeled by the parametric
densities {fθ : θ ∈ Θ ⊂ Rp}, the MDPDE of θ is defined as the minimizer of the DPD between the
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data and fθ with respect to θ, or equivalently as the minimizer of
∫
f1+αθ (y)dy −
1 + α
α
∫
fαθ (y)dGn(y) =
∫
f1+αθ (y)dy −
1 + α
α
1
n
n∑
i=1
fαθ (Yi), (4)
where Gn is the empirical distribution function. At α = 0, this MDPDE coincides with the MLE;
the MDPDEs become more robust but less efficient as α increases, although the extent of loss is
not significant in most cases with small α > 0; see [2] for more details.
Under the censored data set-up of Section 1, let us model the true distribution GX by the
parametric model family F = {Fθ : θ ∈ Θ ⊆ Rp} and denote the density of Fθ by fθ. Based on n
i.i.d. randomly censored observations {Zi, δi}i=1,...,n, as suggested in [1], we define the MDPDE by
using the KMPL estimator ĜX in place of Gn in (4), so that the estimating equation is given by
∫
uθ(y)f
1+α
θ (y)dy −
∫
uθ(y)f
α
θ (y)dĜX(y) = 0, (5)
where uθ = ∇ ln fθ is the likelihood score function, with ∇ representing the gradient with respect
to θ. It is clearly an M-estimator with a model dependent ψ-function given by
ψ(x;θ) = ψα(x;θ) =
∫
uθ(y)f
1+α
θ (y)dy − uθ(x)fαθ (x). (6)
The MDPDE is also Fisher consistent; its estimating equation (5) is unbiased at the model.
Further, unlike general M-estimators defined only through an estimating equation, the MDPDEs
have a solution to the multiple root issue, since there is a proper underlying objective function.
However, for censored data, the MDPDE at α = 0 is, in a strict sense, not exactly the MLE as
studied in [4], since we use the KMPL in place of the empirical distribution function. But it is
closely related to the estimator studied by [24] who called it the “approximate MLE (AMLE)”; this
AMLE will be our standard of comparison. The consistency of the MDPDE has been proved [1,
Theorem 3.1] under much simpler Assumption (B1)–(B5) of Appendix A; its asymptotic normality
follows directly from the general results of M-estimator.
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2.3 Robustness: Influence Function of the Estimators
The influence function (IF) is the most popular and classical tool for the theoretical assessment of
robustness [12]. It indicates a (first order) approximation to the bias in the estimator caused by
infinitesimal contamination at an outlying data point (contamination point) and hence measures
the stability of the estimators. However, the IF of M-estimators and MDPDEs under random
censoring has not been studied in detail, except for few expressions in [28]. Here, we fill this gap
up by developing the general IF theory of M-estimators along with illustration for the MDPDEs.
Suppose Tψ(GX)(= θ0) denotes the statistical functional corresponding to the M-estimator
with a given ψ-function at GX , defined as a solution of (2). Consider the contaminated distribution
G = (1 − )GX + ∧t, where  is the contamination proportion and ∧t denotes the degenerate
distribution at the contamination point t. Then, substituting Tψ(G) for θ0 and G for GX in (2)
and differentiating with respect to  at  = 0, we get the IF of Tψ at GX to have the form
IF(t;Tψ, GX) = ∂
∂
Tψ(G)
∣∣∣∣
=0
= Λ(ψ;Tψ(GX))
−1ψ(t;Tψ(GX)). (7)
Clearly, M-estimators with bounded ψ-functions have bounded IFs and hence are robust with
respect to infinitesimal contaminations. But, if ψ is unbounded, the resulting M-estimator has
unbounded IF, implying its non-robust nature.
Now, using the ψ-function from (6) in Equation (7), we get the IF of the MDPDE functional
Tψα which has the simple form at the model GX = Fθ0 as given by
IF(t;Tψα , Fθ0) =
(∫
uθ0(y)u
T
θ0(y)f
1+α
θ0
(y)dy
)−1 [∫
uθ0(y)f
1+α
θ0
(y)dy − uθ0(t)fαθ0(t)
]
.
Note that, the IF of the MDPDE with α > 0 is bounded for most parametric models, whereas it is
unbounded at α = 0 (non-robust AMLE). Hence, the MDPDEs with α > 0 yield robust estimators.
Example 2.3.1 [MDPDE under the Exponential Model]. Consider the exponential model
family (Exp(θ)) having mean θ > 0 (parameter of interest) and distribution function Fθ(x) = 1−
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e−
x
θ at x > 0. In this case, the ψ-function corresponding to the MDPDE with tuning parameter α >
0 is given by ψα(x; θ) =
(θ−x)
θα+2
e−
αx
θ − α
(1+α)2θα+1
, and hence Λ(ψα; θ0) = (1 + α
2)(1 + α)−3θ−(α+2).
Therefore, the IF of the resulting MDPDE (Tψα) at GX = Fθ0 is given by
IF(t;Tψα , Fθ0) =
(1 + α)3
(1 + α2)
[
(θ0 − t)e−
αt
θ0 − αθ0
(1 + α)2
]
.
Note that, these IFs are bounded for all α > 0 implying the robust nature of those MDPDEs.
However, at α = 0, we get IF(t;Tψ0 , Fθ0) = (θ0 − t) which, being a linear function, is clearly
unbounded and implies the non-robust nature of the classical AMLE. Figure 2a shows their plots
with θ0 = 1; the clear descending nature of the IFs with increasing α further implies their increasing
robustness strengths.
On the other hand, it has been empirically illustrated in [1] that the pure-data efficiency of the
MDPDE decreases slightly with increasing α > 0, but its robustness under contamination increases
significantly yielding smaller finite sample MSE. In Figure 2b, we also present the empirical MSE
of the MDPDEs from a simulation exercise, with 1000 replications, under this Exp(θ) model with
sample size n = 100, true parameter θ0 = 1, 10% (expected) exponential censoring (requires
censoring mean to be 9) and different proportions of contamination from Exp(10). The trade-
offs between the efficiency and robustness of the MDPDEs over the tuning parameter α, and its
advantages under contaminated observations are clearly observed from these figures. 
3 Consistent Estimation of the Asymptotic Variance of M-Estimators
As discussed earlier, the major challenge in developing any test is to get a consistent estimate of
the covariance matrix of the estimator to be used. So, we first need a consistent estimate Σ̂(ψ;θ)
of the covariance matrix Σ(ψ;θ) of the robust M-estimator for a given ψ-function based on the
censored observations {Zi, δi}; here we develop it under the fully parametric model setting.
Under the notation of Section 2, let GX = Fθ0 with θ0 being the true parameter value and
suppose Assumption (A3) holds; then
∫
ψ(x;θ0)dGX(x) =
∫
ψ(x;θ0)dFθ0(x) = 0. Note that, in
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(a) IF (b) Empirical MSE
Figure 2: IFs and empirical MSE of the MDPDEs under exponential model (θ0 = 1) with Exp(9)
censoring. The 100% contamination is taken from Exp(10) for MSE calculation.
view of Slutsky’s theorem, it is enough to consistently estimate Λ(ψ;θ0) and C(ψ;θ0) separately.
Now, under our parametric model assumption, one can easily derive a closed form expression
of Λ(ψ;θ0) =
∫
∂
∂θψ(x;θ0)dFθ0(x). So, assuming its continuity in θ and consistency of the M-
estimator θ̂n, a consistent estimate of Λ(ψ;θ0) is given by Λ(ψ; θ̂n). However, for M-estimators
without the fully parametric model assumption, a non-parametric estimate of Λ(ψ;θ) can also be
obtained as Λ̂n(ψ; θ̂n) =
1
n
∑n
i=1
∂
∂θψ(Xi;θ).
Next, the harder challenge is to estimate C(ψ;θ) which depends on the unknown censoring
distribution GC through GZ and hence cannot be computed explicitly, as in the case of Λ(ψ;θ).
To estimate it, we consider its defining function UZ,δ(·) which is further defined in terms of the
quantities γ0, γ1, γ2 and γ involving the unknown distributions GZ , GZ,0 and GZ,1. However, these
distributions can be estimated empirically, respectively, as
ĜZ,n(z) =
1
n
n∑
i=1
I(Zi ≤ z) and ĜZ,j,n(z) = 1
n
n∑
i=1
I(Zi ≤ z, δi = j), j = 0, 1.
Note that, ĜZ,n and ĜZ,j,n are uniformly consistent for GZ and GZ,j respectively for j = 0, 1.
Plugging ĜZ,n(z) and ĜZ,j,n(z) in the definitions of γ0, γ1, γ2 and γ, we get their consistent
estimators which we denote, respectively, as γ̂0,n, γ̂1,n, γ̂2,n and γ̂n. At the ordered observations
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{Z(i,n), δ[i,n]}, i = 1, . . . , n, they have the explicit forms given by
γ̂0,n(Z(i,n)) = exp

i−1∑
j=1
I(δ[j,n] = 0)
n− j
 , γ̂n(Z(i,n)) =
i−1∑
j=1
nI(δ[j,n] = 0)
(n− j)2 ,
γ̂1,n(Z(i,n);φ) =
1
n− i+ 1
n∑
j=i+1
I(δ[j,n] = 1)φ(Z(j,n))γ̂0,n(Z(j,n)),
γ̂2,n(Z(i,n);φ) =
1
n
 i∑
j=1
I(δ[j,n] = 1)γ̂n(Z(j,n))φ(Z(j,n))γ̂0,n(Z(j,n))
+ γ̂n(Z(i,n))
n∑
j=i+1
I(δ[j,n] = 1)φ(Z(j,n))γ̂0,n(Z(j,n))
 .
Then, assuming continuity of ψ in θ, a consistent estimate of the function UZ,δ(ψj(·,θ)) is given by
ÛZ,δ(ψj(·; θ̂n)) for each j = 1, . . . , p, where ÛZ,δ(φ) = φ(Z)γ̂0,n(Z)δ+ γ̂1,n(Z;φ)(1− δ)− γ̂2,n(Z;φ).
Thus, we finally get a consistent estimator of C(ψ;θ) as
Ĉn(ψ; θ̂n) =
1
n
n∑
i=1
Û(Zi, δi;ψ(·; θ̂n))Û(Zi, δi;ψ(·; θ̂n))T
=
1
n
n∑
i=1
Û(Z(i,n), δ[i,n];ψ(·; θ̂n))Û(Z(i,n), δ[i,n];ψ(·; θ̂n))T (8)
where Û(Z, δ,ψ(·; θ̂n)) =
(
ÛZ,δ(ψ1(·; θ̂n)), · · · , ÛZ,δ(ψp(·; θ̂n))
)T
.
Therefore, the asymptotic covariance matrix Σ(ψ;θ0) of a consistent sequence of M-estimators
θ̂n can be estimated consistently by the estimator Σ̂n(ψ; θ̂n) = Λ(ψ; θ̂n)
−1Ĉn(ψ; θ̂n)Λ(ψ; θ̂n)−1,
or the estimator Σ̂n(ψ; θ̂n) = Λ̂n(ψ; θ̂n)
−1Ĉn(ψ; θ̂n)Λ̂n(ψ; θ̂n)−1.
Let us now illustrate the performance and rate of consistency of the proposed variance estimator
for the MDPDE under the class of Weibull model.
Example 3.1 [MDPDE under Weibull Model]. Consider the Weibull model with parameter
θ = (a, b)T as described in the motivating examples in Section 1. The distribution function of this
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Weibull(a, b) model is given by Fθ(x) = 1 − e−(ax)b at x > 0, so that the MDPDE ψ-function at
an α > 0 is given by (6) with density fθ(x) = ba
bxb−1e−(ax)b and score function
uθ(x) =
 ba(1− (ax)b)
ln(ax)(1− (ax)b) + 1b
 .
Note that the integral in (6) and hence the ψ-function do not have a close form expression in
this Weibull model, unlike the exponential model in Example 2.3.1; they need to be computed
numerically. Similarly, the matrix Λ(ψα;θ0) cannot be expressed in a closed form and so, after
computation of the MDPDE, θ̂n = (ân, b̂n)
T , we can estimate it by Λ̂n(ψ; θ̂n). A consistent
variance estimate of this MDPDE can then be obtained following our proposal described above.
Let us compute the MDPDE and its variance estimate based on simulated samples of various
sizes (n) drawn from Weibull(2,5) distribution along with (expected) 10% censoring from exponen-
tial distribution (this requires the censoring mean to be around 17.4). The process is repeated 1000
times to compute the empirical MSE of the MDPDEs and the average of their variance estimates;
their ratio (say, Rα) is then plotted over n for different α in Figure 3. Note that, a value of Rα close
to one indicates the consistency of our proposed variance estimator for the MDPDE which is seen to
hold for a reasonably moderate sample size n = 200. This ratio is, in fact, quite close to one for all
n ≥ 10 for the scale parameter a whereas we need slightly larger sample sizes n > 50 for the shape
parameter b in the Weibull model. These observations clearly indicate the desired performance of
the proposed variance estimator to be useful in developing robust tests of hypotheses in subsequent
sections. 
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(a) Paramter a (b) Paramter b
Figure 3: The ratio (Rα) of variance estimator and empirical MSE of the MDPDEs of θ = (a, b)
T
under Weibull(a, b) model with true parameters (a, b) = (2, 5) and 10% censoring from Exp(17.4).
4 Robust Tests for One-Sample Problems
4.1 The Wald-Type Tests Statistics
Consider the set-up of randomly censored observations {Zi, δi}i=1,...,n as in the previous sections
with GX ∈ F . The simplest possible hypothesis is then given by
H0 : θ = θ0, against H1 : θ 6= θ0, (9)
where θ0 ∈ Θ is prefixed. However, we here consider a more general class of parametric hypothesis,
also containing this simple one in (9), as given by
H0 : θ ∈ Θ0, against H1 : θ ∈ Θ−Θ0, (10)
where Θ0 is a fixed proper subset of Θ. In most applications, Θ0 is defined in terms of r(≤ p)
restrictions of the form m(θ) = 0 for some function m : Rp → Rr. We assume that the p × r
matrix M (θ) = ∂m(θ)∂θ exists and is continuous in θ with rank(M (θ)) = r. Then, we construct
the Wald-type test statistics for testing (10), based on the robust M-estimators θ̂n of θ associated
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with a given ψ-function, as given by
W ∗n = nm
T
(
θ̂n
) [
MT (θ̂n)Σ̂n(ψ; θ̂n)M(θ̂n)
]−1
m
(
θ̂n
)
, (11)
where Σ̂n(ψ; θ̂n) is a consistent estimator of the variance of θ̂n from Section 3.
Note that, the simple hypothesis given in (9) is a special case of (10) with Θ0 = {θ0}, r = p,
m(θ) = θ − θ0 and M(θ) = Ip, the identity matrix of order p; then W ∗n has a much simpler form
as W ∗n = W 0n = n(θ̂n − θ0)T Σ̂n(ψ; θ̂n)−1(θ̂n − θ0).
Now, using consistency of Σ̂n(ψ; θ̂n), one can show along the lines of [3] that, W
∗
n asymptotically
follows a chi-square distribution (χ2r) with r degrees of freedom under the null hypothesis in (10).
Further, a power approximation at α0-significance level can be obtained as given by
piW ∗n (θ
∗) = P
(
W ∗n > χ
2
r,α|θ = θ∗
) ≈ 1− Φ( n1/2
σ∗ (θ∗)
(
χ2r,α
n
− W¯ (θ∗)
))
, for any θ∗ /∈ Θ0,
where Φ(·) is the standard normal distribution function, χ2r,α0 denote the (1−α0)-th quantile of χ2r ,
W¯ (θ) = mT (θ)
[
MT (θ)Σ(ψ;θ)M(θ)
]−1
m(θ), and σ2∗ (θ
∗) =
(
∂W¯ (θ)
∂θ
)T
θ=θ∗
Σ(ψ;θ∗)
(
∂W¯ (θ)
∂θ
)
θ=θ∗
.
This approximation can be used to derive the sample size requirement while designing the clinical
trial to achieve a desired power in their robust analysis. Also, for any θ∗ /∈ Θ0, lim
n→∞piW
∗
n
(θ∗) = 1,
implying the consistency of the proposed Wald-type tests.
Again, in the line of [3], one can show that the asymptotic distribution of W ∗n under the
contiguous alternative hypotheses H1,n : θ = θn, where θn = θ0 + n
−1/2d, with d ∈ Rp − {0p},
is χ2r (δ), the non-central chi-square distribution with r degrees of freedom and non-centrality
parameter δ, with δ = dTM (θ0) Σ
∗(ψ;θ0)−1M (θ0)T d, where Σ∗(ψ;θ) = MT (θ)Σ(ψ;θ)M(θ).
This will help us to directly obtain the asymptotic contiguous power of our proposed tests for
known censoring or estimate it for unknown censoring mechanism using the consistent estimators
of θ and Σ(ψ;θ).
Example 4.1.1 [MDPDE based Tests under Weibull Model]. Consider the simulation study
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as in Example 3.1 for the MDPDE under Weibull(a, b) model with 10% exponential censoring. Let
us now perform the proposed MDPDE based test for two simple hypotheses H
(1)
0 : (a, b) = (2, 5),
H
(2)
0 : (a, b) = (2.2, 2.3) and two composite hypotheses H
(3)
0 : b = 5, H
(4)
0 : b = 2, assuming
unknown a, against their respective omnibus alternatives at the 5% level of significance. We present
the proportion of rejection among 1000 replications, at sample size n = 100, in Table 2; note that
the hypotheses H
(1)
0 and H
(3)
0 leads to level of the tests whereas the other two hypotheses give the
power against contiguous alternatives. Additionally, to study the robustness of the proposed tests,
we repeat the above simulation exercise by contaminating 5% of each samples by observations from
exponential distribution with mean 5; the corresponding level and power under contamination are
also presented in Table 2. Clearly, even at a slight contamination of 5%, the level and power of the
AMLE based classical Wald test (at α = 0) essentially break down and differ drastically from their
desired values, whereas the proposed MDPDE based Wald-type tests produce highly stable level
and power for α ≥ 0.3. 
Table 2: Simulated proportion of Rejection (level or power) by the MDPDE based Wald-type tests
for different hypotheses under Weibull model with exponential censoring (n = 100)
α Pure Data 5% contaminated Data
H
(1)
0 H
(2)
0 H
(3)
0 H
(4)
0 H
(1)
0 H
(2)
0 H
(3)
0 H
(4)
0
0 0.070 1 0.049 1 0.901 0.313 0.917 0.247
0.1 0.055 1 0.038 1 0.150 0.988 0.194 0.992
0.2 0.053 1 0.034 1 0.096 1 0.108 1
0.3 0.054 1 0.032 1 0.087 1 0.085 1
0.4 0.056 1 0.033 1 0.082 1 0.075 1
0.5 0.058 1 0.038 1 0.074 1 0.075 1
0.6 0.061 1 0.037 1 0.072 1 0.071 1
0.7 0.061 1 0.041 1 0.070 1 0.070 1
0.8 0.059 1 0.043 1 0.069 1 0.069 1
0.9 0.061 1 0.043 1 0.073 1 0.072 1
1 0.063 1 0.037 1 0.069 1 0.072 1
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4.2 Robustness: Influence Analysis
In order to study the robustness of W ∗n through its IF [12], we define the corresponding statistical
functional as (ignoring the multiplier n)
W ∗ψ(GX) = m
T (Tψ(GX))Σ
∗(ψ;Tψ(GX))−1m(Tψ(GX)). (12)
Let θ0 ∈ Θ0 be the true parameter value under (10); we have GX = Fθ0 and m(Tψ(GX)) = 0r
for all ψ-functions under consideration. Hence, the first order IF of W ∗ψ(·) at the null hypothesis
in (10) turns out to be IF(t,W ∗ψ, Fθ0) = 0. So, we need to consider the second order IF of W ∗ψ at
the null hypothesis in (10), which is given by
IF2(t,W ∗ψ, Fθ0) = 2IF(t,Tψ, Fθ0)TM(θ0)Σ∗(ψ;θ0)−1MT (θ0)IF(t,Tψ, Fθ0)
= 2ψ(t;θ0)
TΛ(ψ;θ0)
−1M(θ0)Σ∗(ψ;θ0)−1MT (θ0)Λ(ψ;θ0)−1ψ(t;θ0). (13)
The above second order IF of W ∗ψ is bounded implying the robustness of the proposed Wald-
type tests, whenever the underlying ψ-function is bounded. But, it is non-robust for unbounded
ψ-functions. In particular, the IFs of the MDPDE based Wald-type tests can be derived as a
special case; the corresponding second order IF is bounded for all α > 0 and unbounded for α = 0
in most parametric models. This proves the desired robust nature of these tests at α > 0 and the
non-robust nature of the classical AMLE based Wald test at α = 0.
Let us now study the stability of power and size of the proposed Wald-type tests through the
corresponding influence function analysis. Since these tests are consistent, we consider the asymp-
totic power under the contiguous alternatives H1,n. However, in order to derive the power and level
influence functions, we also consider additional contiguous contamination, assuming GX = Fθ0 , as
FPn,,t =
(
1− √
n
)
Fθn +
√
n
∧t, and FLn,,t =
(
1− √
n
)
Fθ0 +
√
n
∧t, respectively [12]. Let us denote
the asymptotic level and power of the proposed Wald-type test statistics W ∗n under these contam-
inated distributions as αW ∗n (, t) = limn→∞PFLn,,t(W
∗
n > χ
2
r,α) and βW ∗n (θn, , t) = limn→∞PFPn,,t(W
∗
n >
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χ2r,α). Then, the level influence function (LIF) and the power influence function (PIF) of W
∗
n are
defined as
LIF(t;W ∗ψ, Fθ0) =
∂
∂
αW ∗n (, t)
∣∣∣∣
=0
and PIF(t;W ∗ψ, Fθ0) =
∂
∂
βW ∗n (θn, , t)
∣∣∣∣
=0
.
Now, following a similar calculation as in [3], we can show that, under FPn,,t, W
∗
n asymptotically
follows χ2r(δ
∗) distribution, where δ∗ = d˜
T
 (θ0)M(θ0)Σ
∗(ψ;θ0)−1MT (θ0)d˜(θ0), with d˜(θ0) =
d+ IF(t,Tψ, Fθ0). Then, the asymptotic power of W ∗n under FPn,,t can be approximated as
βW ∗n (θn, , t) =
∞∑
v=0
Cv
(
MT (θ0)d˜(θ0),Σ
∗(ψ;θ0)−1
)
P
(
χ2r+2v > χ
2
r,α
)
,
where Cv (t,A) =
(tTAt)
v
v!2v e
− 1
2
tTAt. In particular, substituting d = 0p we get the asymptotic
level of W ∗n under the contaminated distribution FLn,,t as given by αW ∗n (, t) = βW ∗n (θ0, , t) =
∞∑
v=0
Cv
(
MT (θ0)IF(t, Tψ, Fθ0),Σ∗(ψ;θ0)−1
)
P
(
χ2r+2v > χ
2
r,α
)
.
Now we can derive the LIF and PIF of W ∗n by differentiating βW ∗n (θn, , t) and αW ∗n (, t) with
respect to  at  = 0, respectively. Whenever IF(t,Tψ, Fθ0) finite, they are given by
LIF(t,W ∗ψ, Fθ0) = 0, PIF(t,W ∗ψ, Fθ0) = K∗r (S0d)S0IF(t,Tψ, Fθ0),
withK∗p(s) = e
− s
2
∑∞
v=0 s
v−12−v (2v − s)P (χ2p+2v > χ2p,α) /v! and S0 = dTM(θ0)Σ∗(ψ;θ0)−1MT (θ0).
Note that the PIF of the proposed test is bounded implying the power stability under contiguous
contamination, whenever the IF of the M-estimator used is bounded, i.e., whenever the under-
lying ψ-function is bounded, and vice versa. In particular, the MDPDE based tests have stable
asymptotic power with bounded PIF for all α > 0; the PIF of the classical AMLE based Wald test
(at α = 0) is unbounded implying its non-robust nature. Further, for bounded ψ-functions, the
LIF is identically zero which implies that the level of the corresponding Wald-type tests remain
asymptotically stable under a contiguous contamination.
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5 Further Useful Extensions
5.1 Robust Comparison of Two Independent Censored Groups
In any clinical trial study, we generally have two or more independent groups of patients exposed
to different treatments (and control) which need to be compared statistically. Extending the idea
from the previous section, we can also develop the Wald-type tests for robust comparison of two
such censored groups using the M-estimators (and MDPDE). The corresponding uncensored cases
have been studied in [11].
Let us assume that the two independent randomly censored life-time samples of size n1 and
n2 are given from the underlying distribution Fθ1 and Fθ2 , respectively. Given a general function
m(θ1,θ2) from Rp×Rp to Rr, suppose our interest is in testing for the general class of parametric
hypotheses given by
H0 : m(θ1,θ2) = 0r against H1 : m(θ1,θ2) 6= 0r. (14)
The most common special case is to test for the homogeneity of the two life-time distributions
given by m(θ1,θ2) = (θ1−θ2) or the partial homogeneity based on a subset of (multidimensional)
parameter. As before, we need to assume that M i(θ1,θ2) =
∂
∂θi
m(θ1,θ2)
T exists, has rank r and
is continuous with respect to its arguments for each i = 1, 2.
Now, let (1)θ̂n1 and
(2)θ̂n2 denote the M-estimators of θ1 and θ2, respectively, based on each
samples separately corresponding to a given ψ-function. Also, let (i)Σ̂n(ψ;
(i) θ̂ni) be a consistent
variance estimator for (i)θ̂ni , for i = 1, 2, from Section 3. Then, we define the Wald-type test
statistic for testing (14) as
W (2)n1,n2 =
n1n2
n1 + n2
m
(
(1)θ̂n1 ,
(2) θ̂n2
)T
Σ˜n1,n2(
(1)θ̂n1 ,
(2) θ̂n2)
−1m
(
(1)θ̂n1 ,
(2) θ̂n2
)
, (15)
where Σ˜n1,n2(θ1,θ2) =
∑
i=1,2
n1+n2−ni
n1+n2
M i(θ1,θ2)
T (i)Σ̂n(ψ;
(i) θ̂ni)M i(θ1,θ2). We additionally need
to assume that nin1+n2 → ωi ∈ (0, 1), for both i = 1, 2, as n1, n2 → ∞; clearly ω1 + ω2 = 1. Then,
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it is straightforward to show from the asymptotic distribution of the M-estimators that, under the
null hypothesis in (14), W
(2)
n1,n2 asymptotically follows a χ
2
r distribution as n1, n2 → ∞. Thus, the
level-α0 critical region based on W
(2)
n1,n2 for testing (14) is given by {W (2)n1,n2 > χ2r,α0}.
As in the case of the one-sample problem, we can also develop an approximation to the asymp-
totic power for the test based on W
(2)
n1,n2 as well, which is given by
pin1,n2(θ1,θ2) = P
(
W (2)n1,n2 > χ
2
r,α
)
≈ 1− Φ

√
n+m
nm
2
√
l˜∗(θ1,θ2)
[
χ2r,α −
nm
n+m
l˜∗(θ1,θ2)
] ,
whenever ψ(θ1,θ2) 6= 0r, where l˜∗(θ1,θ2) = m(θ1,θ2)T Σ˜n1,n2(θ1,θ2)−1m(θ1,θ2). Note that,
from this approximation, we also get pin1,n2(θ1,θ2)→ 1 as n1, n2 →∞ proving the consistency of
the proposed two-sample tests as well against any fixed alternative.
However, the computation of the asymptotic contiguous power is a bit tricky here, since we
can consider different possible contiguous alternatives for the two-sample case; see the discussion
in [11]. Here, let us consider a class of general contiguous alternatives defined as H1,n1,n2 : θi =
θi,n = θi0 + n
− 1
2
i ∆i, i = 1, 2, for some fixed (θ10,θ20) satisfying m(θ1,θ2) = 0 and (∆1,∆2) ∈
Rp × Rp − {(0p,0p)}. Then, one can show that the asymptotic distribution of W (2)n1,n2 under these
alternatives H1,m,n is χ
2
r(δ˜), where δ˜ = W (∆1,∆2)
T
[
lim
n1,n2→∞
Σ˜n1,n2(θ1,θ2)
]−1
W (∆1,∆2) with
W (∆1,∆2) =
[√
ωMT1 (θ1,θ2)∆1 +
√
1− ωMT2 (θ1,θ2)∆2
]
. These asymptotic results can then
be used directly to compute (or estimate) the asymptotic contiguous power of the proposed test.
Finally, in order to study the robustness of our two-sample Wald-type test statistics W
(2)
n1,n2 , we
defined the corresponding statistical functional as (ignoring the multiplier n1n2n1+n2 )
W˜
(2)
ψ (G1, G2) = m
T (Tψ(G1),Tψ(G2)) Σ˜ψ(Tψ(G1),Tψ(G2))
−1m (Tψ(G1),Tψ(G2)) ,
whereGi denote the true underlying distribution of the i-th sample for each i = 1, 2, and Σ˜ψ(θ1,θ2) =∑
i=1,2
ωiM
T
i (θ1,θ2)Σ(ψ;θi)M i(θ1,θ2). Let us denote, under the null hypothesis in (14), Gi = Fθi0
for i = 1, 2 and define there contaminated versions Gi, = (1− )Gi + ∧ti , respectively, for i = 1, 2.
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Note that, in two sample case, the contamination can be in either of the samples or in both of
them. Following the similar calculations as in Section 4.2, one can show that the first order IF
of the two-sample test functional W˜
(2)
ψ is again zero at the null distribution for either types of
contaminations. The corresponding second order IFs are given by
IF
(i)
2 (ti; W˜
(2)
ψ , Fθ10 , Fθ20)
= 2IF(ti;Tψ, Fθ10)TM i(θ10,θ20)Σ˜ψ(θ10,θ20)−1M i(θ10,θ20)TIF(ti;Tψ,θi0),
for contamination only in the i-th sample (i = 1, 2) at the point ti, and
IF2((t1, t2); W˜
(2)
ψ , Fθ10 , Fθ20) = 2Qψ(t1, t2)
T Σ˜ψ(θ10,θ20)
−1Qψ(t1, t2),
for contamination in both the samples, where
Qψ(t1, t2) = M
T
1 (θ10,θ20)IF(t1;Tψ, Fθ10) +MT2 (θ10,θ20)IF(t2;Tψ, Fθ10).
Note that, these second order IFs are again bounded if the IF of the M-estimator being used is
bounded and the later holds for all bounded ψ-functions. Thus, the MDPDE based two sample
Wald-type tests with any α > 0 yield robust solution under any types of infinitesimal contamination.
Interestingly, for contamination in both the samples, even if the IFs of individual estimators are
not bounded, the proposed test can still be robust having bounded second order IF provided the
term Qψ(t1, t2) is bounded. An example of such case arises while testing for homogeneity of two
samples (H0 : θ1 = θ2) with t1 = t2 (i.e., same contamination in both samples), where Qψ(t1, t2)
becomes identically zero under the null.
As in the one sample case, we can also derive the level and power influence function of the
proposed two-sample tests by extending the arguments from [11] and we omit the details for brevity.
It can be shown that, whenever the IF of the underlying estimators are bounded, the LIF is again
zero and PIF is a linear function (or combination) of the IFs of these estimators used. In all case,
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the robustness implication turns out to be the same as above; our test will be robust in both level
and power when using the bounded ψ-function or in particular the MDPDEs with α > 0.
5.2 Robust Tests against One-Sided Alternatives
Although we have developed the theory of the proposed Wald-type tests for both sided alternatives,
it can also be applied to one sided alternatives with suitable modifications when the null dimension is
one. Such one sided alternatives commonly arise, for example, in studying the efficacy of a treatment
against the control group, i.e., testing if the average lifetime of treatment group is greater than that
of the control group. The main idea for testing such one sided alternative would be to consider
the (suitably) signed square-root of the proposed both-sided test statistics having χ21 asymptotic
null distribution (when the dimension of the null parameter space is one); the resulting square-root
statistic then asymptotically has the standard normal null distribution and yields robust inference
against the one-sided alternatives.
For illustration, we consider the null hypothesis in (14) with r = 1, but against the one-sided
alternative as given by
H0 : m(θ1,θ2) = 0 against H1 : m(θ1,θ2) > 0. (16)
The modified version of the proposed test statistic for testing (16) is then obtained from the two-
sided Wald-type test statistics W
(2)
n1,n2 as
W˜ (2)n1,n2 = sign
(
m
(
(1)θ̂β,
(2) θ̂β
))√
W
(2)
n1,n2 =
√
n1n2
n1 + n2
m
(
(1)θ̂n1 ,
(2) θ̂n2
)
√
Σ˜n1,n2(
(1)θ̂n1 ,
(2) θ̂n2)
. (17)
Note that Σ˜β(θβ,θβ) is now a scalar since r = 1. Clearly, under the null hypothesis in (16), W˜
(2)
n1,n2
asymptotically follows the standard normal distribution and hence the level-α0 critical region for
testing (16) is given by
{
W˜
(2)
n1,n2 > z1−α0
}
, where z1−α0 denotes the (1 − α)-th quantile of the
standard normal distribution.
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One can further derive the detailed theory of this one-sided test statistics in a similar fashion
as in the previous sections. In particular, we can show that this test is also consistent at any
fixed alternatives and is robust when the ψ-function is chosen to be bounded. For brevity, we
skip the details here and refer the readers to [11] where the similar theory has been developed
for the MDPDE based one-sided tests with uncensored data; standard modifications as described
previously will lead to the results for the present case of randomly censored data.
6 Real-Life Applications: MDPDE based Wald-type Tests
We now present some real-life applications of the proposed Wald-type tests based on the MDPDE in
different two-arm clinical trials including those mentioned briefly in the introduction. Based on the
nature of their cumulative hazard functions (as in Figure 1), we model the data from each arm of a
clinical trial separately as well as the combined data of both the arms by the Weibull distributions
with parameters (a1, b1), (a2, b2) and (a0, b0), respectively; we stick to the same notation for all
trials for easier understanding. We then apply the proposed test procedures for several hypotheses
on these parameters ais and bis under the actual data as well as after removing the outliers from
the data; for brevity only few interesting cases are reported below.
6.1 Veteran Lung Cancer trial
We first consider the right censored data from a benchmark clinical trial study in survival analysis,
namely the Veterans’ Administration Lung Cancer study, which is a randomized trial with two
treatment regimens for lung cancer. Arm A represents standard treatment whereas Arm B is
the treatment under test; more details about the study can be found in [13, 17]. The MDPDEs
of the Weibull parameters fitted to these data are presented in Table 1. As noted earlier, the
robust estimate of bi is close to one for all three cases (i = 0, 1, 2), but the MLE of b2 and b0 are
little away from one; so we need to check if they are significantly different from one. Note that a
Weibull distribution with shape parameter b = 1 is nothing but the simple exponential distribution
and hence a test for the hypothesis H0 : β = 1 is equivalent to test for exponentiality against
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Weibull alternatives. A close investigation yields three large outlying response values (uncensored)
among the 68 patients in Arm B, which cause the difference in the MLE. We apply the proposed
MDPDE based Wald-type tests for these data with and without these outliers; the p-values of two
particular hypotheses, namely one composite hypothesis H0 : b2 = 1 with unknown a2 and one
simple hypothesis H0 : a2 = 85, b2 = 1 against their respective omnibus alternatives, are shown in
Figure 4 for different α ≥ 0. Note that, for the classical Wald test at α = 0 the presence or absence
of the outliers leads to a difference in the final conclusion, whereas the proposed tests with α > 0.2
give stable inference which is not affected by outliers.
(a) H0 : b0 = 1 (b) H0 : a2 = 85, b2 = 1
Figure 4: P-values for the MDPDE based Wald-type test over α for Veteran Lung Cancer trial
[Solid line: Full data; Dotted line: Outlier deleted data].
Further we can apply the proposed two sample testing procedures to robustly compare the data
in two arms. For illustrations consider the problem of comparing the shape of the distributions
for both arms, which can be done by testing the composite hypothesis H0 : b1 = b2 with unknown
a1, a2. The p-value for testing this null hypothesis against the one sided alternative H1 : b1 > b2
using the classical Wald test under the full data turns out to be 0.047 which becomes 0.23 after
removing the outliers from Arm 2. Thus, the inference at 5% level of significance based on the
classical MLE based Wald test turns around under the presence of outlying observations. However,
the p-value resulting from the MDPDE based proposed Wald-type test for the above composite
two-sample problems are 0.14, 0.39 and 0.56 at α = 0.2, 0.5, 1, respectively, under the full data. The
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outlier deleted data also lead to insignificant p-values in each of these cases. This clearly indicates
the robust nature of our proposal in the two-sample problem.
6.2 Small-Cell Lung Cancer trial
We now consider randomly right-censored survival time data from another two arm clinical trial on
the Small-cell lung cancer with two different treatments [26]. The data on both the arms contain
few outlying observations which make the MLE different from the robust MDPDE of the Weibull
parameters as presented in Table 1. We again apply the proposed Wald-type tests based on these
MDPDEs under the full data as well as the outlier deleted data. The resulting p-values are shown
in Figure 5 for the composite hypotheses H0 : a1 = 770 with unknown b1 and H0 : b2 = 2 with
unknown a2, against their respective omnibus alternatives. Once again, it is pretty clear that the
proposed tests produce more stable inference than the classical Wald test but we need slightly
larger α (≥ 0.5 or thereabouts) due to the presence of heavy outliers.
(a) H0 : a1 = 770 (b) H0 : b2 = 2
Figure 5: P-values for the MDPDE based Wald-type test over α for Small-Cell Lung Cancer trial
[Solid line: Full data; Dotted line: Outlier deleted data].
6.3 Breast and Ovarian Cancer trial
Our third example is from a Breast and Ovarian cancer (BOC) trial where the two arms contain
the randomly censored survival times of the breast cancer patients and the Ovarian cancer pa-
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(a) H0 : a0 = 2920, b0 = 1.3 (b) H0 : b2 = 1.45
Figure 6: P-values for the MDPDE based Wald-type test over α for Breast & Ovarian Cancer trial
[Solid line: Full data; Dotted line: Outlier deleted data].
tients, respectively. The data are available in the recent R-package survminer and the parameter
estimates under the fitted Weibull model are presented in Table 1. Again some large outlying
observations affect the MLE significantly. Motivated by their robust estimates, we perform the
proposed MDPDE based test for the simple hypothesis H0 : a0 = 2920, b0 = 1.3 and the composite
hypothesis H0 : b2 = 1.45 with unknown a2, against their respective omnibus alternatives and plot
the resulting p-values in Figure 6 for both the full data and outlier deleted data. The proposed tests
with slightly larger α > 0 are again seen to produce robust inference in contrast to the non-robust
classical Wald test (at α = 0).
6.4 Gastric Carcinoma trial
Our next example is based on another two arm clinical trial data on 90 locally unresectable gastric
cancer patients randomized into two equal arms [19]. Patients in arms A and B are, respectively,
treated with only chemotherapy and a combined treatment of chemotherapy and radiotherapy. The
data were initially produced by the Gastrointestinal Tumor Study Group [31] and later analyzed
by many scientists [see, e.g., 32]. Interestingly, this study is different from the previous examples
in that the data in both the arms contain some early failures, a different type of outliers, which
also affects the MLE significantly and forces it to be different from the robust parameter estimates
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(a) H1 : b1 6= 1 (b) H1 : b1 < 1
Figure 7: P-values for the MDPDE based Wald-type test over α for testing exponentiality of Arm
A (i.e., H0 : b1 = 1) of Gastric Carcinoma trial against two alternatives [Solid line: Full data;
Dotted line: Without two early failures].
(Table 1). Suppose we want to test for the exponentiality of the data in Arm A, i.e., to test for
the composite null hypothesis H0 : b1 = 1 assuming a1 to be unknown. We apply the proposed
MDPDE based tests against the both sided alternative H1 : b1 6= 1 and also against the one sided
alternative H1 : b1 < 1; the resulting p-values are reported in Figure 7 based on the full data as
well as after removing two early failures from Arm A. Note that all the estimates of b1 in Table
1 are larger than one, but the MLE based classical Wald test fails to reject the null hypothesis in
favor of either alternative in presence of the early failures. The proposed MDPDE based tests, on
the other hand, produce robust inference at α ≥ 0.4 even under the presence of such early failure
observations.
6.5 Head and Neck Cancer trial
We now present another analysis of a clinical trial data for head and neck cancer treatment [8],
which has earlier been used to illustrate the advantages of MDPDE over MLE in [1]. The two
arms of the dataset represent the radiation therapy alone (arm A) and a combination of radiation
therapy and chemotherapy (arm B), respectively. Here, we restrict our attention to arm A, which
contains seven (7) large outliers among a total of 51. Further, nine (9) patients in this arm were
lost to follow-up, producing a high censoring rate of about 20%. As demonstrated in [1], the robust
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MDPDE of the Weibull parameter (a1, b1) is approximately (250, 1.47) at α = 1, which fit the
majority of the data quite well, compared to the non-robust AMLEs (418, 0.98); see Table 3 for
MDPDEs at other α. Further, after deleting the 7 outliers from the data, the corresponding AMLE
becomes approximately (239, 1.46) which is quite close to the robust MDPDEs derived from the
full data including outliers.
(a) H0 : a1 = 250, b1 = 1.4 (b) H0 : a1 = 418
Figure 8: P-values for the MDPDE based Wald-type test over α for Head and Neck Cancer trial
[Solid line: Full data; Dotted line: Outlier deleted data].
Motivated by the above analyses, we present the p-values obtained by the proposed MDPDE
based tests of two particular hypotheses in Figure 8; one simple hypothesis H0 : a1 = 250, b1 = 1.4,
and one composite hypothesis H0 : a1 = 418 with unknown b1, against their respective omnibus
alternatives. Note that, due to the presence of outliers, the AMLE based classical Wald-test soundly
produces incorrect inferences, as compared to the results obtained after removing the outliers. But,
the proposed Wald-type tests can successfully ignore the effect of outliers and produce stable results
for all α ≥ 0.4.
6.6 Myeloma Data
We finally present a different medical data example containing no outliers to illustrate the equally
effective performance of our proposed tests. The data consist of the lifetimes of 65 multiple myeloma
patients from their diagnosis, of which seventeen (17) were still alive at the end of the study and
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Table 3: MDPDEs of (a, b) in the Weibull model fitted to two datasets
Parameter α
0 (AMLE) 0.1 0.3 0.5 0.7 1
Head and Neck Cancer data
a 417.98 412.42 386.62 321.25 254.92 249.52
b 0.98 0.99 1.03 1.16 1.42 1.47
Myeloma data
a 32.94 33.06 33.19 32.88 32.10 30.46
b 1.06 1.05 1.03 1.02 1.03 1.06
hence censored [13, 20]. We fit the Weibull(a, b) model to these data; the AMLE and MDPDEs
are presented in Table 3. Note that, all estimates are pretty close to each other due to the absence
of outliers. Based on these estimates, in Figure 9, we have plotted the p-values obtained by the
proposed MDPDE based Wald-type tests for the hypotheses H0 : a = 30, b = 1 and H0 : b = 1 with
unknown a, against their respective omnibus alternatives. Clearly the p-values are also very similar
to the classical test for any α ≥ 0. This is highly important as we do not often know anything
about the presence or the extent of outliers in our real-life data. This example illustrates that the
proposed robust test can be quite similar to the classical Wald test in the absence of outliers with
all the methods giving similar inference.
(a) H0 : a = 30, b = 1 (b) H0 : b = 1
Figure 9: P-values for the MDPDE based Wald-type test over α for Myeloma data [Solid line: Full
data; Dotted line: Outlier deleted data].
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7 Concluding Remarks
In this paper, we have considered the fully parametric robust inference for survival data with
random censoring. We have proposed robust Wald-type tests for both simple and composite null
hypotheses using the M-estimators including the MDPDEs; for this purpose, a consistent estimator
for their asymptotic variance is developed. We have also derived the asymptotic and robustness
theory of the proposed Wald-type tests based on general M-estimators. The robustness of the
proposed Wald-type tests are also studied theoretically through IF of the test statistics, LIF and
PIF. Extensions for general two sample problems and one-sided alternatives are also discussed along
with several real-life applications. A natural follow up would include robust Wald-type tests for
the regression set-up with randomly censored observations, which we hope to take up in the future.
A Appendix: Assumptions Required for Asymptotic Results
Assumptions related to General M-estimators: For any distribution function F , let us define
∆F (x) = F (x)−F (x−) and denote the upper bound of the support F by τF = sup{x : F (x) < 1}.
(A1) Either (i) for each j, there exists some b < τGZ such that ψj(x;θ0) = 0 for b < x ≤ τGZ ;
or, (ii) τGX ≤ τGC , with strict inequality when GC is continuous at τGX and ∆GX(τGX ) > 0.
(A2) For each j = 1, . . . , p, ψj(x;θ0) satisfies E [ψj(Z;θ0)γ0(Z)δ]
2 =
∫
ψ2j (z;θ0)γ
2
0(z)dGZ,1(z) <
∞ and ∫ |ψj(x;θ0)| γ1/2(x)dGX(x) <∞.
(A3) θ0 is the unique root of (2).
(A4) The p× p matrix C(ψ;θ0), defined in Section 2.1, is finite element-wise.
(A5) The p× p matrix Λ(ψ;θ0), defined in Section 2.1, is finite and non-singular.
(A6) For each i, j = 1, . . . , p, g(x,θ) = ∂∂θiψj(x;θ0) is absolutely integrable with respect to GX
and satisfies any one of the following conditions:
(i) g(x,θ) is continuous at θ0 uniformly in x,
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(ii)
∫
supθ:|θ−θ0|≤δ |g(x,θ)− g(x;θ0)| dGX(x) = hδ → 0 as δ → 0,
(iii) g(x,θ) is continuous in x for θ in a neighborhood of θ0, and lim
θ→θ0
||g(·,θ)− g(·,θ0)||v = 0,
(iv)
∫
g(x,θ)dGX(x) is continuous at θ = θ0, and g(x,θ) is continuous in x for θ in a
neighborhood of θ0, and lim
θ→θ0
||g(·,θ)− g(·,θ0)||v <∞,
(v)
∫
g(x,θ)dGX(x) is continuous at θ = θ0, and
∫
g(x,θ)dĜX(x)→P
∫
g(x,θ0)dGX(x) <
∞, uniformly for θ in a neighborhood of θ0.
(A7) There exists a compact set K ⊆ Rp such that, for each j, infθ/∈K
∣∣∫ ψj(x;θ)dGX(x)∣∣ > 0.
Assumptions related to MDPDEs:
(B1) The model distribution Fθ has support independent of θ which is the same as that of GX .
(B2) There is an open subset ω ⊆ Θ containing the true parameter θ0 such that, for all θ ∈ ω,∫
f1+αθ <∞ and fθ(x) is thrice continuously differentiable in θ for almost all x in its support.
(B3)
∫
fθ(x)
1+αdx and
∫
fθ(x)
αdGX(x) are thrice differentiable and the derivatives can be inter-
changed with the integral. Also, EGX
[
∂Vθ(X)
∂θ
]
<∞, where Vθ(x) =
∫
f1+αθ (y)dy− 1+αα fαθ (x).
(B4) The matrix Λ(ψα;θ) has all entries finite and is positive definite.
(B5) For all θ ∈ ω, every third derivatives of Vθ(x) with respect to θ is bounded by some function
of x not depending on θ and having finite expectation with respect to GX .
References
[1] Basu, S., Basu, A., and Jones, M. C. (2006). Robust and efficient parametric estimation for
censored survival data. Ann. Inst. Stat. Math., 58(2), 341–355.
[2] Basu, A., Harris, I. R., Hjort, N. L., and Jones, M. C. (1998). Robust and efficient estimation
by minimising a density power divergence. Biometrika, 85, 549–559.
32
[3] Basu, A., Mandal, A., Martin, N., and Pardo, L. (2016). Generalized Wald-type tests based on
minimum density power divergence estimators. Statistics, 50(1), 1–26.
[4] Borgan, O. (1984). Maximum likelihood estimation in parametric counting process models, with
applications to censored failure time data. Scand. J. Stat., 11, 1-16.
[5] Collett, D. (2003). Modelling Survival Data in Medical Research. Chapman Hall, London, U.K.
[6] Cox, D. R., and Oakes, D. (1984). Analysis of Survival Data. Chapman Hall, London, U.K.
[7] Crowder, M. J., Kimber, A. C., Smith, R. L., and Sweeting, T. J. (1991). Statistical Analysis
of Reliability Data. Chapman Hall, London, U.K.
[8] Efron, B. (1988). Logistic regression, survival analysis, and the KaplanMeier curve. J. Amer.
Stat. Assoc., 83, 414–425.
[9] Ghosh, A. and Basu A. (2017). Robust and Efficient Parameter Estimation based on Censored
Data with Stochastic Covariates. Statistics, 51(4), 801–823.
[10] Ghosh, A., Mandal, A., Martin, N., and Pardo, L. (2016). Influence Analysis of Robust Wald-
type Tests. J. Mult. Anal., 147, 102–126.
[11] Ghosh, A., Martin, N., Basu, A., and Pardo, L. (2018). A new class of robust two-sample
Wald-type tests. Int. J. Biostat., to appear.
[12] Hampel, F. R., E. Ronchetti, P. J. Rousseeuw, and W. Stahel (1986). Robust Statistics: The
Approach Based on Influence Functions. New York, USA: John Wiley & Sons.
[13] Heritier, S., Cantoni, E., Copt, S., and Victoria-Feser, M. P. (2009). Robust methods in Bio-
statistics (Vol. 825). John Wiley and Sons.
[14] Hjort, N. L. (1985). Discussion of the paper by P. K. Andersen & O. Borgan. Scand. J. Stat.,
12, 141–150.
33
[15] Hosmer, D. W., Lemeshow, S. and May, S. (2008). Applied Survival Analysis: Regression
Modeling of Time-to-Event Data. John Wiley & Sons.
[16] James, I. R. (1986). On estimating equations with censored data. Biometrika, 73, 35–42.
[17] Kalbfleisch, J. D., and Prentice, R. L. (2011). The statistical analysis of failure time data (Vol.
360). John Wiley and Sons.
[18] Kaplan, E. L., and Meier, P. (1958). Nonparametric estimation from incomplete observations.
J. Amer. Stat. Assoc., 53 (282), 457–481.
[19] Klein, J.P. and Moeschberger, M.L. (2003). Survival Analysis Techniques for Censored and
Truncated Data, Second Edition. Springer-Verlag, New York.
[20] Krall, J.M., Uthoff, V.A., and Harley, J. B. (1975). A Step-up Procedure for Selecting Variables
Associated with Survival. Biometrics, 31, 49–57.
[21] Lai, T. Z., and Ying, Z. (1994). A missing information principle and M-estimators in regression
analysis with censored and truncated data. Ann. Stat., 22, 1222–1255.
[22] Lawless, J.F. (2003). Statistical Models and Methods for Lifetime Data, Second Edition. John
Wiley & Sons, Inc. New York.
[23] Locatelli, I., Marazzi, A., and Yohai, V. J. (2011). Robust accelerated failure time regression.
Comput. Stat. Data Anal., 55, 874–887.
[24] Oakes, D. (1986). An approximate likelihood procedure for censored data. Biometrics, 42,
177–182.
[25] Reid, N. (1981). Influence functions for censored data. Ann. Stat., 9, 78–92.
[26] Ying, Z., Jung, SH, and Wei, LJ (1995). Median regression analysis with censored data. J.
Amer. Stat. Assoc., 90, 178-184.
34
[27] Wang, J. L. (1995). M-estimators for censored data: strong consistency. Scand. J. Stat., 22,
197–206.
[28] Wang, J. L. (1999). Asymptotic Properties of M-Estimators Based on Estimating Equations
and Censored Data. Scand. J. Stat., 26(2), 297–318.
[29] Wang, S., Hu, T., Xiang, L., and Cui, H. (2015). Generalized M-estimation for the accelerated
failure time model. Statistics, 50(1), 114–138.
[30] Zhou, W. (2010). M-estimation of the accelerated failure time model under a convex discrep-
ancy function. J. Stat. Plann. Inf., 140, 2669–2681.
[31] Gastrointestinal Tumor Study Group (1982). A comparison of combination chemotherapy and
combined modality therapy for locally advanced gastric carcinoma. Cancer, 49(9), 1771–1777.
[32] Stablein DM, Koutrouvelis IA. A two-sample test sensitive to crossing hazards in uncensored
and singly censored data (1985). Biometrics, 41(3), 643–652.
35
